Merck & Co., Inc. (NYSE:MRK) Shares Sold by Dubuque Bank & Trust Co.

Dubuque Bank & Trust Co. reduced its stake in Merck & Co., Inc. (NYSE:MRKGet Rating) by 1.2% in the 2nd quarter, Holdings Channel reports. The firm owned 10,246 shares of the company’s stock after selling 129 shares during the quarter. Dubuque Bank & Trust Co.’s holdings in Merck & Co., Inc. were worth $934,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Bromfield Sneider Wealth Advisors acquired a new stake in Merck & Co., Inc. in the 1st quarter valued at $79,000. Hikari Power Ltd increased its holdings in Merck & Co., Inc. by 5.0% in the 1st quarter. Hikari Power Ltd now owns 23,630 shares of the company’s stock valued at $1,939,000 after purchasing an additional 1,130 shares in the last quarter. Financial Management Professionals Inc. increased its holdings in Merck & Co., Inc. by 9.3% in the 2nd quarter. Financial Management Professionals Inc. now owns 3,414 shares of the company’s stock valued at $311,000 after purchasing an additional 291 shares in the last quarter. ACG Wealth grew its stake in shares of Merck & Co., Inc. by 5.6% during the first quarter. ACG Wealth now owns 13,523 shares of the company’s stock valued at $1,110,000 after acquiring an additional 722 shares in the last quarter. Finally, Mascoma Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 36.4% during the first quarter. Mascoma Wealth Management LLC now owns 926 shares of the company’s stock valued at $76,000 after acquiring an additional 247 shares in the last quarter. 73.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Erste Group Bank upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Thursday, August 25th. Atlantic Securities raised their target price on Merck & Co., Inc. from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Cowen raised their target price on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research note on Monday, June 27th. Cowen raised their target price on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research note on Monday, June 27th. Finally, SVB Leerink raised their target price on Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a research note on Monday, September 12th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus price target of $98.28.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $87.51 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.39 and a debt-to-equity ratio of 0.66. The firm’s 50-day moving average price is $88.83 and its two-hundred day moving average price is $87.81. Merck & Co., Inc. has a 52-week low of $71.50 and a 52-week high of $95.72. The stock has a market capitalization of $221.69 billion, a P/E ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.20. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The firm had revenue of $14.59 billion for the quarter, compared to analysts’ expectations of $13.85 billion. During the same quarter last year, the company posted $1.31 earnings per share. Merck & Co., Inc.’s revenue was up 28.0% on a year-over-year basis. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 7.33 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a dividend of $0.69 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.15%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 42.27%.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.